

Se Hoon Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/40718/publications.pdf>

Version: 2024-02-01

250
papers

9,835
citations

94269

37
h-index

43802

91
g-index

252
all docs

252
docs citations

252
times ranked

12836
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. <i>Nature Medicine</i> , 2015, 21, 449-456.	15.2	1,592
2	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018, 24, 1449-1458.	15.2	1,071
3	Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 268-273.	0.8	667
4	Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone. <i>Journal of Clinical Oncology</i> , 2012, 30, 1513-1518.	0.8	564
5	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-405.	0.8	450
6	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 2102-2114.	13.9	427
7	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 3130-3136.	0.8	370
8	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1637-1651.	5.1	233
9	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. <i>Cancer Discovery</i> , 2019, 9, 1388-1405.	7.7	155
10	Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. <i>JCO Global Oncology</i> , 2020, 6, 414-438.	0.8	140
11	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€“05): a single-arm, phase 1bâ€“2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1066-1076.	5.1	130
12	Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2019, 20, 1454-1466.	5.1	125
13	Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. <i>Oncology Reports</i> , 2011, 25, 1517-24.	1.2	111
14	Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. <i>Genome Medicine</i> , 2020, 12, 47.	3.6	107
15	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. <i>Oncotarget</i> , 2015, 6, 40360-40369.	0.8	85
16	Simvastatin plus capecitabineâ€“cisplatin versus placebo plus capecitabineâ€“cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study. <i>European Journal of Cancer</i> , 2014, 50, 2822-2830.	1.3	79
17	Polymorphic markers associated with severe oxaliplatinâ€“induced, chronic peripheral neuropathy in colon cancer patients. <i>Cancer</i> , 2012, 118, 2828-2836.	2.0	76
18	Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 248-258.	5.1	73

#	ARTICLE	IF	CITATIONS
19	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, 165-169.	1.0	71
20	FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. <i>Modern Pathology</i> , 2016, 29, 1095-1103.	2.9	70
21	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	0.8	68
22	High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. <i>Pathology Research and Practice</i> , 2020, 216, 152881.	1.0	67
23	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	2.9	66
24	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA); Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 T <i>FGFR</i> alterations (FGFRalt).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4503-4503.	0.8	63
25	Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 314.	1.3	62
26	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. <i>Cancer Science</i> , 2021, 112, 305-313.	1.7	62
27	Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. <i>Oncotarget</i> , 2017, 8, 13320-13328.	0.8	60
28	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015, 15, 154.	1.1	58
29	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015, 6, 28211-28222.	0.8	57
30	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4700-4709.	3.2	54
31	ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4001-4001.	0.8	53
32	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. <i>Oncotarget</i> , 2015, 6, 25619-25630.	0.8	48
33	ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA3-LBA3.	0.8	47
34	MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. <i>Oncotarget</i> , 2016, 7, 43492-43503.	0.8	45
35	The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer. <i>Scientific Reports</i> , 2015, 5, 9289.	1.6	43
36	Acquired resistance to LY2874455 in <i>FGFR2</i>-amplified gastric cancer through an emergence of novel <i>FGFR2-ACSL5</i> fusion. <i>Oncotarget</i> , 2017, 8, 15014-15022.	0.8	42

#	ARTICLE	IF	CITATIONS
37	Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 477-480.	0.6	41
38	Bridging genomics and phenomics of gastric carcinoma. International Journal of Cancer, 2019, 145, 2407-2417.	2.3	40
39	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. Journal of Geriatric Oncology, 2017, 8, 170-175.	0.5	39
40	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 1045-1056.	5.1	39
41	Exome Sequencing Identifies Early Gastric Carcinoma as an Early Stage of Advanced Gastric Cancer. PLoS ONE, 2013, 8, e82770.	1.1	36
42	Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract. Translational Oncology, 2018, 11, 37-42.	1.7	35
43	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent <i>In Vitro</i> Antitumor Activity in Gastric Cancer Cell Lines with <i>FGFR2</i> Amplification. Molecular Cancer Therapeutics, 2014, 13, 2527-2536.	1.9	34
44	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. Journal of Gastric Cancer, 2016, 16, 105.	0.9	34
45	High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer. PLoS ONE, 2014, 9, e111693.	1.1	34
46	HER2-positive gastric cancer with concomitant <i>MET</i> and/or <i>EGFR</i> overexpression: A distinct subset of patients for dual inhibition therapy. International Journal of Cancer, 2015, 136, 1629-1635.	2.3	33
47	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. Oncoimmunology, 2017, 6, e1356150.	2.1	32
48	Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. Oncotarget, 2017, 8, 42478-42486.	0.8	32
49	Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial. Radiotherapy and Oncology, 2015, 117, 171-177.	0.3	31
50	Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA-Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis. JCO Precision Oncology, 2017, 1, 1-15.	1.5	31
51	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 979-985.	1.1	30
52	Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. Clinical Sarcoma Research, 2014, 4, 13.	2.3	28
53	Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and <i>FGFR</i> alterations (FGFRa): Phase 2 continuous versus intermittent dosing.. Journal of Clinical Oncology, 2018, 36, 411-411.	0.8	28
54	Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. Cancer Research and Treatment, 2018, 50, 488-494.	1.3	28

#	ARTICLE	IF	CITATIONS
55	Second-line chemotherapy for patients with oesophagogastric adenocarcinoma. <i>Lancet Oncology</i> , 2014, 15, 8-10.	5.1	27
56	A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring <i>HRAS</i> Mutations. <i>Clinical Cancer Research</i> , 2020, 26, 5113-5119.	3.2	27
57	Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). <i>Cancer Research and Treatment</i> , 2018, 50, 1252-1259.	1.3	27
58	Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial. <i>Oncology</i> , 2019, 97, 38-43.	0.9	26
59	Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer. <i>Translational Cancer Research</i> , 2020, 9, 3367-3374.	0.4	26
60	Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 382-386.	0.7	25
61	Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. <i>Journal of Cancer</i> , 2016, 7, 1174-1180.	1.2	25
62	Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. <i>BMC Cancer</i> , 2018, 18, 1103.	1.1	25
63	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. <i>Scientific Reports</i> , 2014, 4, 7592.	1.6	24
64	Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>BMC Cancer</i> , 2017, 17, 211.	1.1	24
65	The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015, 6, 33358-33368.	0.8	24
66	Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU). <i>Journal of Clinical Oncology</i> , 2023, 41, 43-53.	0.8	24
67	Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. <i>Cancer</i> , 2007, 109, 732-740.	2.0	23
68	Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. <i>BMC Cancer</i> , 2015, 15, 693.	1.1	23
69	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2 Amplified Gastric Cancer Patient-Derived Cell Model. <i>Translational Oncology</i> , 2017, 10, 469-475.	1.7	23
70	Development of mesenchymal subtype gene signature for clinical application in gastric cancer. <i>Oncotarget</i> , 2017, 8, 66305-66315.	0.8	23
71	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017, 8, 96656-96667.	0.8	23
72	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 782-790.	1.2	22

#	ARTICLE	IF	CITATIONS
73	Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study. <i>BMC Palliative Care</i> , 2015, 14, 41.	0.8	21
74	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , 2017, 8, 11094-11104.	0.8	21
75	Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 1970, 47, 72-77.	1.3	20
76	Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 256-260.	0.6	20
77	The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC). <i>Journal of Cancer</i> , 2017, 8, 1395-1399.	1.2	20
78	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. <i>Cancers</i> , 2019, 11, 187.	1.7	20
79	Comprehensive pharmacogenomic characterization of gastric cancer. <i>Genome Medicine</i> , 2020, 12, 17.	3.6	20
80	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	1.4	20
81	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017, 8, 3237-3245.	0.8	20
82	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016, 48, 553-560.	1.3	19
83	Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2018, 25, 596-603.	0.5	19
84	EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 394-394.	0.8	19
85	Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 61-67.	0.7	18
86	The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2017, 8, 2809-2815.	1.2	18
87	Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma. <i>BMC Urology</i> , 2018, 18, 68.	0.6	18
88	Rogaratinib treatment of patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression.. <i>Journal of Clinical Oncology</i> , 2018, 36, 494-494.	0.8	18
89	Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6504-6504.	0.8	18
90	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <i>BMC Cancer</i> , 2015, 15, 530.	1.1	17

#	ARTICLE	IF	CITATIONS
91	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. <i>Journal of Cancer</i> , 2016, 7, 1044-1048.	1.2	17
92	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 140-146.	1.0	17
93	Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-14.	1.0	17
94	Clinical scoring system for the prediction of survival of patients with advanced gastric cancer. <i>ESMO Open</i> , 2020, 5, e000670.	2.0	17
95	ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5015-5015.	0.8	17
96	Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2015, 8, 40-46.	1.7	16
97	NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. <i>ESMO Open</i> , 2016, 1, e000009.	2.0	16
98	Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy. <i>Journal of Urology</i> , 2018, 200, 989-995.	0.2	16
99	Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 222-232.	1.5	16
100	KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4599-TPS4599.	0.8	16
101	MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines. <i>Oncotarget</i> , 2017, 8, 105727-105734.	0.8	16
102	Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 27-31.	0.4	15
103	Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4043-4043.	0.8	15
104	Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 65-65.	0.8	15
105	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <i>Oncotarget</i> , 2016, 7, 24088-24096.	0.8	15
106	Critical role of XBP1 in cancer signalling is regulated by PIN1. <i>Biochemical Journal</i> , 2016, 473, 2603-2610.	1.7	14
107	A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. <i>BMC Urology</i> , 2016, 16, 46.	0.6	14
108	Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials. <i>Oncologist</i> , 2017, 22, 1169-1177.	1.9	14

#	ARTICLE	IF	CITATIONS
109	Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis. <i>Cancer Research and Treatment</i> , 2016, 48, 1274-1285.	1.3	14
110	A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 375-383.	1.6	13
111	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e3.	1.0	13
112	First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 432-432.	0.8	13
113	A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 76-81.	0.9	12
114	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , 2018, 18, 348.	0.9	12
115	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. <i>Radiotherapy and Oncology</i> , 2018, 129, 306-312.	0.3	12
116	Comparative effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17. <i>Cancer Medicine</i> , 2019, 8, 5431-5437.	1.3	12
117	Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS256-TPS256.	0.8	12
118	The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. <i>Korean Journal of Internal Medicine</i> , 2015, 30, 88.	0.7	12
119	Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2013, 45, 285-294.	1.3	12
120	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1231-1237.	1.2	11
121	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018, 95, 344-352.	0.9	11
122	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2825.	1.8	11
123	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 153-161.	1.3	11
124	Chemotherapy in Advanced Gastric Cancer Patients Associated with Disseminated Intravascular Coagulation. <i>Cancer Research and Treatment</i> , 2014, 46, 27-32.	1.3	11
125	A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs.) Tj ETQq1 1 0.784314 rgBT /Overlook Research and Treatment, 2017, 49, 816-823.	1.3	11
126	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , 2015, 15, 747.	1.1	10

#	ARTICLE	IF	CITATIONS
127	BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. <i>Translational Oncology</i> , 2016, 9, 197-202.	1.7	10
128	A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma. <i>Clinical Sarcoma Research</i> , 2016, 6, 8.	2.3	10
129	Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130. <i>Cancer Research</i> , 2021, 81, CT042-CT042.	0.4	10
130	Reducing tumor invasiveness by ramucirumab and TGF α 2 receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model. <i>Cancer Medicine</i> , 2021, 10, 7253-7262.	1.3	10
131	Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer. <i>Radiation Oncology Journal</i> , 2016, 34, 34-44.	0.7	10
132	High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer. <i>Journal of Cancer</i> , 2019, 10, 3172-3178.	1.2	9
133	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. <i>Radiotherapy and Oncology</i> , 2020, 152, 19-25.	0.3	9
134	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092679.	1.4	9
135	Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 107492-107499.	0.8	9
136	Current Status and Challenges of Cancer Clinical Trials in Korea. <i>Cancer Research and Treatment</i> , 2016, 48, 20-27.	1.3	9
137	Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer. <i>Cancers</i> , 2021, 13, 6345.	1.7	9
138	Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. <i>Translational Oncology</i> , 2015, 8, 288-294.	1.7	8
139	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2018, 11, 353-357.	1.7	8
140	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , 2019, 12, 597-601.	1.7	8
141	Role of Adjuvant Chemotherapy in Advanced Stage Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: Competing Risk Analysis after Propensity Score-Matching. <i>Journal of Cancer</i> , 2019, 10, 6896-6902.	1.2	8
142	Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	1.4	8
143	Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130. <i>Cancer Research</i> , 2021, 81, CT040-CT040.	0.4	8
144	Clinical Experience of Male Primary Choriocarcinoma at the Samsung Medical Center. <i>Cancer Research and Treatment</i> , 2021, 53, 874-880.	1.3	8

#	ARTICLE	IF	CITATIONS
145	Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses. <i>Cancers</i> , 2021, 13, 59.	1.7	8
146	Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2015, 21, 4268.	1.4	8
147	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , 2019, 51, 876-885.	1.3	8
148	A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer. <i>BMC Urology</i> , 2017, 17, 63.	0.6	7
149	The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. <i>Journal of Cancer</i> , 2018, 9, 1791-1796.	1.2	7
150	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 1611-1615.	1.2	7
151	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	0.6	7
152	Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	7
153	Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4512-4512.	0.8	7
154	Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer. <i>Journal of Cancer</i> , 2016, 7, 1711-1715.	1.2	6
155	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. <i>Journal of Cancer</i> , 2018, 9, 2910-2915.	1.2	6
156	Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (≥ 45 Years) With Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 5811-5820.	0.5	6
157	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 501-508.	1.1	6
158	TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer. <i>Pathology Research and Practice</i> , 2020, 216, 152820.	1.0	6
159	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021, 99, 365-372.	0.9	6
160	Detection of Aberrant Glycosylation of Serum Haptoglobin for Gastric Cancer Diagnosis Using a Middle-Up-Down Glycoproteome Platform. <i>Journal of Personalized Medicine</i> , 2021, 11, 575.	1.1	6
161	Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy. <i>Cancer Research and Treatment</i> , 2022, 54, 894-906.	1.3	6
162	Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation. <i>Journal of Cancer</i> , 2018, 9, 3394-3399.	1.2	5

#	ARTICLE	IF	CITATIONS
163	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Cancer</i> , 2019, 10, 3140-3144.	1.2	5
164	A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer. <i>BMC Urology</i> , 2019, 19, 30.	0.6	5
165	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. <i>Frontiers in Oncology</i> , 2019, 9, 1327.	1.3	5
166	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. <i>Targeted Oncology</i> , 2020, 15, 185-192.	1.7	5
167	Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. <i>Cancers</i> , 2020, 12, 943.	1.7	5
168	2020 Korean guidelines for the management of metastatic prostate cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 491-514.	0.7	5
169	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2427-2435.	1.2	5
170	First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4051-4051.	0.8	5
171	Multicenter phase III trial of adjuvant chemoradiotherapy in stomach tumors 2 (ARTIST 2).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS228-TPS228.	0.8	5
172	Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS712-TPS712.	0.8	5
173	Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4547-4547.	0.8	5
174	The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. <i>Oncotarget</i> , 2017, 8, 73974-73980.	0.8	5
175	Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure. <i>Current Problems in Cancer</i> , 2022, 46, 100848.	1.0	5
176	Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma. <i>Translational Oncology</i> , 2017, 10, 304-310.	1.7	4
177	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 225-231.	1.0	4
178	Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2021, 12, 460-466.	1.2	4
179	First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2570-2570.	0.8	4
180	Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4557-4557.	0.8	4

#	ARTICLE	IF	CITATIONS
181	Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on <i>FGFR</i> mRNA overexpression.. Journal of Clinical Oncology, 2020, 38, 527-527.	0.8	4
182	Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma.. Journal of Clinical Oncology, 2016, 34, 355-355.	0.8	4
183	Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study. Cancer Research and Treatment, 2019, 51, 1269-1274.	1.3	4
184	Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study. Investigative and Clinical Urology, 2020, 61, 588.	1.0	4
185	Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification. American Journal of Translational Research (discontinued), 2019, 11, 4508-4515.	0.0	4
186	Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder. Investigative and Clinical Urology, 2022, 63, 168.	1.0	4
187	Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma. Cancers, 2022, 14, 2354.	1.7	4
188	Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2019, 17, e1137-e1146.	0.9	3
189	Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis. Journal of Cancer, 2020, 11, 7202-7208.	1.2	3
190	Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.. Journal of Clinical Oncology, 2021, 39, 4524-4524.	0.8	3
191	Abstract CT187: Overall survival (OS) by response during "induction" from the global, randomized Phase III IMvigor130 study of atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated metastatic urothelial carcinoma (mUC). Cancer Research, 2021, 81, CT187-CT187.	0.4	3
192	Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy.. Journal of Clinical Oncology, 2016, 34, 4016-4016.	0.8	3
193	Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer.. Journal of Clinical Oncology, 2018, 36, 4021-4021.	0.8	3
194	Selumetinib plus docetaxel as second-line chemotherapy in KRAS mutant, KRAS amplified or MEK signature gastric cancer patients: First arm of the umbrella trial in GC through the molecular screening, VIKTORY trial.. Journal of Clinical Oncology, 2018, 36, 4061-4061.	0.8	3
195	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, 3576-3576.	0.8	3
196	Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2019, 37, 3023-3023.	0.8	3
197	A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer. BMC Cancer, 2021, 21, 1281.	1.1	3
198	Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). Gastric Cancer, 2022, 25, 609-618.	2.7	3

#	ARTICLE	IF	CITATIONS
199	The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2004, 19, 79.	1.1	2
200	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2522-2522.	0.8	2
201	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3104-3104.	0.8	2
202	Multiple Opportunistic Infections Related to Hypercortisolemia due to Adrenocortical Carcinoma: A Case Report. <i>Infection and Chemotherapy</i> , 2021, 53, 797.	1.0	2
203	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4049-4049.	0.8	2
204	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. <i>Anticancer Research</i> , 2014, 34, 6585-91.	0.5	2
205	Irinotecan and Cisplatin Combination Chemotherapy Plus Concurrent Thoracic Irradiation for Patients with Limited Disease Small Cell Lung Cancer. <i>Journal of Lung Cancer</i> , 2011, 10, 49.	0.2	1
206	To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 2173-2178.	1.2	1
207	Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4056-4056.	0.8	1
208	Interim safety analysis from a randomized, open-label, multicenter, phase III trial of capecitabine plus oxaliplatin (XELOX) versus capecitabine (X) as first-line chemotherapy in elderly patients with advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 158-158.	0.8	1
209	The NEXT-2 (Next Generation Personalized Tx with Plasma DNA Genomics Trial-2 in Refractory Solid) Tj ETQq1 1 0.784314 rgBT /Overl e12540-e12540.	0.8	1
210	Prognostic value of the metastatic lymph node (N) ratio in the adjuvant chemoradiotherapy in stomach tumors (ARTIST) phase III trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 4038-4038.	0.8	1
211	Molecular characterization of urothelial carcinoma of bladder and upper urinary tract.. <i>Journal of Clinical Oncology</i> , 2017, 35, 361-361.	0.8	1
212	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14501-e14501.	0.8	1
213	Results from the safety interim analysis of the Adjuvant chemoRadioTherapy In Stomach Tumors 2 (ARTIST 2) randomized, multi-center clinical trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16029-e16029.	0.8	1
214	The role of pazopanib in various histologic subtypes of metastatic soft tissue sarcomas.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10586-10586.	0.8	1
215	Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4008-4008.	0.8	1
216	Overall survival beyond first-line docetaxel in patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2017, 35, e570-e570.	0.8	1

#	ARTICLE	IF	CITATIONS
217	Development of a novel patient-derived preclinical model from malignant effusions in patients with tyrosine kinase inhibitor resistant clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2017, 35, 445-445.	0.8	1
218	VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met (+), and vistusertib/paclitaxel in RICTOR(+) GC.. Journal of Clinical Oncology, 2017, 35, 4024-4024.	0.8	1
219	Erdafitinib in high-risk patients (pts) with advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2019, 37, 4543-4543.	0.8	1
220	Tipifarnib, a farnesyltransferase inhibitor, for metastatic urothelial carcinoma harboring HRAS mutations.. Journal of Clinical Oncology, 2020, 38, 5086-5086.	0.8	1
221	Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy Followed by Radical Cystectomy: A Single-Center Retrospective Study. The Korean Journal of Urological Oncology, 2020, 18, 194-200.	0.1	1
222	A prospective phase II trial of neoadjuvant nivolumab plus gemcitabine/cisplatin chemotherapy in muscle-invasive urothelial carcinoma of bladder.. Journal of Clinical Oncology, 2022, 40, 494-494.	0.8	1
223	Comprehensive landscape of tumor angiogenesis via integrating RNA sequencing and three-dimensional microphysiological system.. Journal of Clinical Oncology, 2022, 40, e16058-e16058.	0.8	1
224	In reply to Mauer et al. "Statistical methodology is crucial in prognostic factor-analysis of health-related quality of life". Quality of Life Research, 2008, 17, 1045-1046.	1.5	0
225	Perceptions of clinical trials in gastrointestinal/hepatobiliary cancer patients: A comprehensive survey in a Korean tertiary hospital.. Journal of Clinical Oncology, 2012, 30, e13094-e13094.	0.8	0
226	A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma.. Journal of Clinical Oncology, 2013, 31, e15613-e15613.	0.8	0
227	A retrospective, multicenter analysis of the clinicopathologic features of extra-gastrointestinal stromal tumor (EGIST).. Journal of Clinical Oncology, 2014, 32, 36-36.	0.8	0
228	Natural history of untreated patients who had metastatic biliary tract cancer (BTC) with good performance status (PS).. Journal of Clinical Oncology, 2014, 32, 362-362.	0.8	0
229	Natural history of untreated patients who had metastatic biliary tract cancer (BTC) with good performance status (PS).. Journal of Clinical Oncology, 2014, 32, e15106-e15106.	0.8	0
230	Do all patients with HER2-positive gastric/GEJ cancer benefit from trastuzumab?. Journal of Clinical Oncology, 2015, 33, 185-185.	0.8	0
231	Clinical features of metastatic renal cell carcinoma patients with intrinsic resistance to sunitinib: A Korean multicenter study.. Journal of Clinical Oncology, 2015, 33, 462-462.	0.8	0
232	Clinicians' preference of adjuvant S-1 versus capecitabine plus oxaliplatin after curative gastrectomy.. Journal of Clinical Oncology, 2015, 33, e15025-e15025.	0.8	0
233	A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM).. Journal of Clinical Oncology, 2015, 33, TPS4138-TPS4138.	0.8	0
234	Comprehensive genomic profiling of metastatic gastric cancer undergoing palliative chemotherapy at Samsung Medical Center using custom targeted deep sequencing (CancerSCAN [®]).. Journal of Clinical Oncology, 2015, 33, e22173-e22173.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Molecular profiling of patient derived cells (PDCs) from metastatic cancer patients using CancerSCAN: Highly profiled models to test the efficacy of genome-directed therapy in cancer.. Journal of Clinical Oncology, 2015, 33, e22241-e22241.	0.8	0
236	A retrospective feasibility analysis of biweekly reduced dose docetaxel in Korean patients with castration-resistant, metastatic prostate cancer.. Journal of Clinical Oncology, 2016, 34, e638-e638.	0.8	0
237	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. Journal of Clinical Oncology, 2016, 34, 4091-4091.	0.8	0
238	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. Journal of Clinical Oncology, 2017, 35, e14622-e14622.	0.8	0
239	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. Journal of Clinical Oncology, 2018, 36, e24234-e24234.	0.8	0
240	Detection of targetable fusions using FusionPlex in oncology patients.. Journal of Clinical Oncology, 2018, 36, e24238-e24238.	0.8	0
241	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.. Journal of Clinical Oncology, 2019, 37, 213-213.	0.8	0
242	Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with integrated genomic profiling.. Journal of Clinical Oncology, 2019, 37, 4064-4064.	0.8	0
243	Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs. Translational Cancer Research, 2019, 8, 2107-2112.	0.4	0
244	PD-L1 expression as a prognostic marker in patients with advanced biliary tract cancer.. Journal of Clinical Oncology, 2020, 38, e16679-e16679.	0.8	0
245	Phase II study of biweekly docetaxel plus androgen-deprivation therapy (ADT) in patients with previously-untreated, metastatic, prostatic adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, e17580-e17580.	0.8	0
246	A clinical scoring system for survival prediction in advanced gastric cancer.. Journal of Clinical Oncology, 2020, 38, 436-436.	0.8	0
247	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. Journal of Gynecologic Oncology, 0, 29, .	1.0	0
248	345â€¦Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)., 2020, , .		0
249	Genomic sequencing for bladder urothelial carcinoma and its clinical implications for immunotherapy.. Journal of Clinical Oncology, 2022, 40, 551-551.	0.8	0
250	A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma. Frontiers in Oncology, 2022, 12, 874385.	1.3	0